Herter, S., Herting, F., Muth, G., van Puijenbroek, E., Schlothauer, T., Ferrara, C., Brady, K., Lang, S., Bacac, M., Mössner, E., Umana, P. and Klein, C. (2018) “GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity”, Haematologica. Pavia, Italy, 103(2), pp. e78-e81. doi: 10.3324/haematol.2017.178996.